magnolin과 aschantin의 항암효과와 분자기전 연구 = Molecular mechanisms of the anti-cancer activity of magnolin and aschantin

목차 (Table of Contents)

• Ⅰ. Abstract ·················································································································1
• Ⅱ. Introduction ··········································································································3
• Ⅲ. Materials and Methods ···················································································15
• Ⅳ. Results ·················································································································30
• 1. Magnolin suppresses NF-κB transactivation activity ···················30
• 2. Magnolin inhibits EGF-induced cell migration in JB6 Cl41 cells··35
• 3. Magnolin inhibits migration and invasion of human lung cancer cells ··················································································································40
• 4. Magnolin inhibits epithelial-mesenchymal transition ······················46
• 5. Aschantin suppresses cell proliferation by inhibition of G1/S cell cycle transition in JB6 Cl41 cells ···························································52
• 6. Aschantin selectively suppresses Akt/GSK3β signaling pathway, but not ERKs/RSKs signaling pathway ·················································55
• 7. Aschantin targets the active pocket of mTOR kinase ·····················59
• 8. Inhibition of mTOR/Akt signaling pathway by aschantin suppresses AP-1 transactivation activity through GSK3β-mediated c-Jun degradation ····································································65
• 9. Aschantin inhibits EGF-induced neoplastic cell transformation ································································································································70
• 10. Aschantin suppresses anchorage-independent colony growth of cancer cells ·······································································································77
• Ⅴ. Discussion ··········································································································83
• Ⅵ. References ·········································································································93